Intravenous aflibercept in patients with platinum‐resistant, advanced ovarian cancer: Results of a randomized, double‐blind, phase 2, parallel‐arm study

Abstract

Aflibercept at a dose of either 2 mg/kg or 4 mg/kg was generally well tolerated but did not meet the primary endpoint for response.